Keloid. Hypertrophic scar
Conditions
Interventions
Intervention 1: Intervention group: Intralesional injection of vitamin D ampoule from Caspian Pharmaceutical Company will be prescribed to patients. Vitamin D ampoule 300,000 units will be injected at
an average of 6 sessions is considered the duration of the patient's treatment. Intervention 2: Control group: Intralesional injection of triamcinolone from EXIR with a concentration of 40 mg per mill
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willingness and cooperation to participate in the study All patients with two or more keloids The duration of lesions should be less than 5 years and they have not been treated yet keloids with different sizes up to 5 cm and in different parts of the body
Exclusion criteria
Exclusion criteria: keloid on face active infection in or near the keloid site pregnant or lactating patients patients with underlying diseases such as diabetes, mental illness, cancer and heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Keloid score in the Vancouver Scar scale. Timepoint: Vancouver scar scale upon arrival, 3, 6, 9, 12, 15 weeks after each injection session until the lesion is completely flattened or up to 6 sessions. Method of measurement: Vancouver scar scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction from treatment. Timepoint: End of treatment. Method of measurement: Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSedigheh Sananzadeh
Ahvaz University of Medical Sciences
Outcome results
None listed